^
Association details:
Biomarker:No biomarker
Cancer:Hairy Cell Leukemia
Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Ibrutinib, vemurafenib (with or without rituximab) or moxetumomab pasudotox are appropriate options for progressive disease following second-line therapy.